Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | CCR1 | P32246 | 3/20 | 0.47 |
| ▸ | CCR5 | P51681 | 3/20 | 0.47 |
| ▸ | CCR8 | P51685 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | METAP1 | P53582 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.47 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | TP53 | P04637 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | ALPL | P05186 | 2/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3142441 | 0.92 | KDM4E (0.42) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL3142540 | 0.88 | KDM4E (0.39) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL3128890 | 0.87 | MECP2 (0.53) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL3142307 | 0.84 | METAP2 (0.39) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL3142709 | 0.84 | KDR (0.44) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL3132456 | 0.82 | GAA (0.42) | SMN1; SMN2NPC1RAB9APKMMEN1 | |
| SCHEMBL3136919 | 0.81 | KDR (0.45) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL30608756 | 0.81 | KDM4E (0.61) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL19782866 | 0.81 | KDM4E (0.61) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL2885850 | 0.80 | CDK2 (0.49) | KDM4ELMNACCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642354-B2 | Use treating nervous system disorders, as neuroprotectants, gastrointestinal disorders, cardiovascular disorders; e.g. 2-(5-phenylpyridin-2-ylamino)-6-pyridin-2-ylpyrimidine | ICAGEN, INC. (US) | 2010-01-05 | — | — | US | claimed |
| EP-1742935-B1 | POLYCYCLIC PYRAZINES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN INC (US) | 2010-02-24 | — | — | EP | disclosed |
| US-7642354-B2 | Use treating nervous system disorders, as neuroprotectants, gastrointestinal disorders, cardiovascular disorders; e.g. 2-(5-phenylpyridin-2-ylamino)-6-pyridin-2-ylpyrimidine | ICAGEN, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| EP-1742935-A1 | POLYCYCLIC PYRAZINES AS POTASSIUM ION CHANNEL MODULATORS | Icagen, Inc. (US) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005121126-A1 | POLYCYCLIC PYRAZINES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN, INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050239800-A1 | Polycyclic pyrazines as potassium ion channel modulators | ICAGEN, INC. (US) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239800-A1 | Polycyclic pyrazines as potassium ion channel modulators | KCNJ2, KCNH2, KCNJ1 | KDM4E 1618/4885LMNA 3729/4885CCR1 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.